Plus   Neg

Amicus Therapeutics Inc. (FOLD) Is Sinking On Phase 3 Study Results

Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline (GSK) announced the 6-month primary treatment period results from the first Phase 3 study of oral migalastat HCl monotherapy in males and females with Fabry disease. The study did not achieve statistical significance according to the pre-specified primary endpoint analysis.

Amicus Therapeutics traded in a narrow range throughout Wednesday's session and finished up by 0.11 at $5.77. The stock is now down 2.80 on 637K shares after the bell.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT